259 related articles for article (PubMed ID: 33571163)
1. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
[TBL] [Abstract][Full Text] [Related]
2. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
Tebas P; Stein D; Tang WW; Frank I; Wang SQ; Lee G; Spratt SK; Surosky RT; Giedlin MA; Nichol G; Holmes MC; Gregory PD; Ando DG; Kalos M; Collman RG; Binder-Scholl G; Plesa G; Hwang WT; Levine BL; June CH
N Engl J Med; 2014 Mar; 370(10):901-10. PubMed ID: 24597865
[TBL] [Abstract][Full Text] [Related]
3. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690741
[No Abstract] [Full Text] [Related]
4. Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller.
Migueles SA; Chairez C; Lin S; Gavil NV; Rosenthal DM; Pooran M; Natarajan V; Rupert A; Dewar R; Rehman T; Sherman BT; Adelsberger J; Leitman SF; Stroncek D; Morse CG; Connors M; Lane HC; Kovacs JA
JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415245
[TBL] [Abstract][Full Text] [Related]
5. Harnessing CD8
Warren JA; Clutton G; Goonetilleke N
Front Immunol; 2019; 10():291. PubMed ID: 30863403
[TBL] [Abstract][Full Text] [Related]
6. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
7. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
[TBL] [Abstract][Full Text] [Related]
9. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
11. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
12. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
13. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
15. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
Maier DA; Brennan AL; Jiang S; Binder-Scholl GK; Lee G; Plesa G; Zheng Z; Cotte J; Carpenito C; Wood T; Spratt SK; Ando D; Gregory P; Holmes MC; Perez EE; Riley JL; Carroll RG; June CH; Levine BL
Hum Gene Ther; 2013 Mar; 24(3):245-58. PubMed ID: 23360514
[TBL] [Abstract][Full Text] [Related]
16. Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.
Lee S; Almeida CA; French MA; Price P
Clin Exp Immunol; 2004 Oct; 138(1):110-5. PubMed ID: 15373912
[TBL] [Abstract][Full Text] [Related]
17. [Deep lung--cellular reaction to HIV].
Tavares Marques MA; Alves V; Duque V; Botelho MF
Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
[TBL] [Abstract][Full Text] [Related]
18. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.
Papasavvas E; Kostman JR; Thiel B; Pistilli M; Mackiewicz A; Foulkes A; Gross R; Jordan KA; Nixon DF; Grant R; Poulin JF; McCune JM; Mounzer K; Montaner LJ
J Clin Immunol; 2006 Jan; 26(1):40-54. PubMed ID: 16418802
[TBL] [Abstract][Full Text] [Related]
20. CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy.
Carvalho-Silva WHV; Andrade-Santos JL; Guedes MCDS; Crovella S; Guimarães RL
Gene; 2020 May; 741():144568. PubMed ID: 32165289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
